替格瑞洛联合阿司匹林治疗急性冠脉综合征的临床疗效及护理观察  

Clinical Study of Ticagrelor with Asprin in Treating Acute Coronary Syndrome

作　　者：王莉[1] 陈静[1] 贾艳梅[1] 李文华[1] 

机构地区：[1]徐州医学院附属医院心内科,徐州221002

出　　处：《中国医药导刊》2014年第8期1243-1244,1246,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨替格瑞洛联合阿司匹林治疗急性冠脉综合征的疗效及出血情况。方法:选择心内科住院治疗的164名急性冠脉综合征患者,随机分为2组,两组均常规给予阿司匹林及低分子肝素治疗,并分别给予替格瑞洛或氯吡格雷共治疗14天。观察用药后临床疗效、血小板数目变化、凝血功能改变及出血情况。结果:应用氯吡格雷或替格瑞洛均可显著改善患者临床症状,且两组组间比较差异有统计学意义(P<0.05)。在两组患者中治疗后的血小板计数及凝血指标均较治疗前明显改变(P<0.05)。替格瑞洛组并未发现出血增多的现象。结论:对急性冠脉综合征患者,与氯吡格雷相比,替格瑞洛可以在不增加出血事件的基础上更有效的改善患者的临床症状。To investigate the clinical effect and safety of ticagrelor with aspirin and low-molecular-weight in treating acute coronary syndrome.Methods： 164 in-patients with acute coronary syndrome and were randomly divided into 2 groups. The ticagrelor group （T group） and clopidogrel group（C group） was performed with ticagrelor or clopidogrel respectively, based on aspirin and low-molecular-weight. The treatment was lasted 14 days. During that, we observed the clinical effect, the number of platelet, coagulation function and the incidence of bleeding.Results：Both ticagrelor and clopidogrel can ameliorate the syndrome markedly, and the difference was significant （P〈0.05） between the groups. The platelet count and coagulation parameters after the treatment were alterd obviously compared with pretherapy, also the difference was significant （P〈0.05）.Conclusion：Compared with clopidogrel, treating with ticagrelor can significantly improve the clinic symptom without increasing the rate of bleeding.

关 键 词：替格瑞洛 氯吡格雷 急性冠脉综合征 临床观察 

分 类 号：R473.5[医药卫生—护理学]